Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Vivos Therapeutics Posts Sales Gain and Smaller Loss, but Cash Position Stays Precarious

The sleep apnoea devices group grew third-quarter sales by almost a quarter on the prior quarter and cut its loss, while Nasdaq signed off on its equity position after an October deal.

17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news

Vivos Therapeutics, a US business selling sleep apnoea devices and related services, has reported a stronger third quarter, with sales of $6.4m for the three months to 30 September 2026. That is 24% above the figure for the preceding quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Vivos Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →